https://www.businesswire.com/news/home/20201005005381/en/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash Today, Bristol Myers announced it's buying MyoKardia (MYOK-Q) ifor US$13.1 billion cash. MyoKardia makes drugs to fight heart disease and heart conditions, including mavacamten, a drug for which they will file an application in Q1-2021. The stock has gotten really cheap. He loves this deal.
MyoKardia is a American stock, trading under the symbol MYOK-Q on the NASDAQ (MYOK). It is usually referred to as NASDAQ:MYOK or MYOK-Q
In the last year, there was no coverage of MyoKardia published on Stockchase.
MyoKardia was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for MyoKardia.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year 0 stock analysts on Stockchase covered MyoKardia. The stock is worth watching.
On 2020-11-16, MyoKardia (MYOK-Q) stock closed at a price of $224.91.